<div class="container">

<table style="width: 100%;"><tr>
<td>betablocker500</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>FDA dataset for beta blockers with 500 adverse events</h2>

<h3>Description</h3>

<p>A 501 by 9 data matrix of a contingency table processed from
the FDA Adverse Event Reporting System (FAERS) database. This dataset covers
a specific period from Q1 2021 to Q4 2023.
</p>


<h3>Usage</h3>

<pre><code class="language-R">betablocker500
</code></pre>


<h3>Format</h3>

<p>A data matrix with 501 rows and 9 columns.
</p>


<h3>Details</h3>

<p>A 501 by 9 data matrix of a contingency table from the FDA Adverse
Event Reporting System (FAERS) database, covering the period from Q1 2021 to
Q4 2023.
</p>
<p>The 500 rows correspond to the AEs with the highest overall
frequency (row marginals) reported during the period, and 1 row for Other
AEs.
The reported AEs - "Off label use" and "Drug ineffective" have been excluded.
</p>
<p>The dataset includes the following 9 columns: Acebutolol, Atenolol,
Bisoprolol, Carvedilol, Metoprolol, Nadolol, Propranolol, Timolol, and Other.
</p>
<p>The marginal totals for each column are as follows:
Acebutolol: 62,164, Atenolol: 36,619, Bisoprolol: 134,297,
Carvedilol: 35,922, Metoprolol: 88,387, Nadolol: 11,191,
Propranolol: 56,444, Timolol: 16,077, Other: 76,926,859.
</p>
<p>Also refer to the supplementary material of:
</p>
<p>Ding, Y., Markatou, M., &amp; Ball, R. (2020). An evaluation of statistical
approaches to postmarketing surveillance. Statistics in Medicine, 39(7),
845-874
</p>
<p>for the data generation process. The quarterly files can be found in
<a href="https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html">https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html</a>.
</p>


<h3>Examples</h3>

<pre><code class="language-R">data(betablocker500)
head(betablocker500)

</code></pre>


</div>